The American College of Cardiology (ACC) has a long history of developing documents (eg,
decision pathways, health policy statements, appropriate use criteria) to provide members …

Early recognition of coagulopathy is necessary for its prompt correction and successful
management. Novel approaches, such as point-of-care testing (POC) and administration of …

Importance Direct oral anticoagulants (DOACs), comprising apixaban, rivaroxaban,
edoxaban, and dabigatran, are commonly used medications to treat patients with atrial …

Background Andexanet alfa is approved (FDA “accelerated approval”; EMA “conditional
approval”) as the first specific reversal agent for factor Xa (FXa) inhibitor-associated …

Background and Purpose: It is unestablished whether andexanet alfa, compared with
guideline-based usual care including prothrombin complex concentrates, is associated with …

Background Well-designed studies with sufficient sample size comparing andexanetáalfa vs
4-factor prothrombin complex concentrate (4F-PCC) in routine clinical practice to evaluate …

Abstract Oral factor Xa (FXa) inhibitors significantly reduce incidence of stroke and
thromboembolic events in patients with atrial fibrillation or venous thromboembolism. Due to …

Aim: We describe the real-world utilization and outcomes associated with managing oral
factor Xa inhibitor (FXai)-related major bleeds. Materials & methods: Electronic records from …

Background The optimal dosing strategy of four-factor prothrombin complex concentrate (4F-
PCC) to treat oral factor Xa (FXa) inhibitor-associated bleeding has not been established …

Background Outcomes following andexanet alfa reversal of factor Xa inhibitors in patients
requiring urgent or emergent invasive procedures are lacking. This study aimed to describe …